https://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1600 a year (including GST in Australia).

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

2020 - The Year In Review

A Year In The Grass - Medical Marijuana Review

Dr Boreham's Crucible: Micro-X

Budget 2020 Special Edition; Comment & Analysis

Cyclopharm: US Technegas Trial Meets Endpoints Early

Biotech Daily 1st Medical Marijuana Survey

CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims

Biotech Daily Editorial: Covid-19 Spruikers, Please Stop !

All the Dope on Medicine, Marijuana, Cannabis & Hemp

  


 2020 BDI-40 Up 24%, Big Caps 6%; ASX200 Down 1.5%

Amplia Up 550%, Alterity 271%, Telix 170%, Immutep 166%

 January 1, 2021

The Biotech Daily Top-40 Index (BDI-40) climbed 1.7 percent in December to close the year up 23.7 percent to a record collective market capitalization of $18,348 million.
 
Despite, or because of, the coronavirus, biotech had a very good year.
 
The benchmark S&P ASX200 fell 1.5 percent for the year to December 31, while the Nasdaq Biotechnology Index (NBI) was up 25.7 percent, and the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed a further 6.0 percent for the year, although down 5.2 percent in December.
 
CSL was up 2.9 percent to close the year at $128,840 million, Resmed rose 25.8 percent to $39,622 million, with Cochlear down 4.4 percent to $12,425 million.
 
Twenty-four of the BDI-40 stocks were up in 2020, with 12 up more than 100 percent and 20 up more than 50 percent; while 16 fell - with eight down by more than 20 percent.
 
While Amplia was the best of the BDI-40, up 550.0 percent to $26 million, it was from a very low base of $4 million.
 
More significantly, the other Dr Christian Behrenbruch-founded company, Telix, was the best of the BDI-20 up 169.7 percent for the year to December 31, to $1,060 million (welcome to the Billion Dollar Club). Other big-hitters in the BDI-20 were Immutep (166.3%), Cyclopharm (118.5%), Polynovo (97.0%) and Genetic Signatures (95.2%).
 
Including Amplia, the Second 20 had nine companies up by more than 100 percent: Alterity (270.6%), Optiscan (250.0%), Imugene (243.5%), Kazia (239.5%), Proteomics (232%), Osprey (176.9%), Universal Biosensors (126.5%) and Patrys (104.8%).
 
Avita led the falls, down 61.2 percent to $530 million, followed by Ellex (54.1%), Pharmaxis (41.3%), Neuren 40.7%), Compumedics (37.3%), Next Science (28.3%), Actinogen (25%), Clinuvel (21.6%), Medical Developments (19.2%) and Opthea (19.2%).
 
Cannabis Corner recovered 38.6 percent in 2020 to a collective market capitalization of $1,660 million, but still 13.2 percent from its July 31, 2019 high of $1,913 million.
 
On the Nasdaq, Queensland’s Protagonist climbed 312.5% to $1,126 million, Israel’s Redhill with Australian assets was up 29.9 percent for the year to $395 million but Eyepoint (formerly Psivida) fell 45.8 percent to $129 million.
 
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Dec 31, 2020 
 
 
5-Year Big Caps (Cochlear, CSL, Resmed) to Dec 31, 2020


BDI-40 ($m) v S&P ASX200 – Year to Dec 31, 2020 
(current, raw data)
 

  

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At December 31, 2020

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear
   Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: 
   https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/